EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Smoking Cessation Interventions in the Lung Cancer Screening Setting

Paul M Cinciripini, Jennifer A Minnix, George Kypriotakis, Jeremy Erasmus, Diane Beneventi, Maher Karam-Hage, Kelly Carpenter, Robert J Volk, Brett Carter, Myrna C B Godoy, Chad Strange, Ya-Chen Tina Shih und 3 weitere

JAMA Internal Medicine · 01.03.2025 · 185 (3) · 284

DOI: 10.1001/jamainternmed.2024.7288 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.03.2025. Verfasst von Paul M Cinciripini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Early Detection of Cancer, Lung Neoplasms, Smoking Cessation, Tobacco Use Cessation Devices. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The optimal configuration of a smoking cessation intervention in a lung cancer screening (LCS) setting has not yet been established.

Objective

To evaluate the efficacy of 3 tobacco treatment strategies of increasing integration and intensity in the LCS setting. Design, Setting, and Participants In this randomized clinical trial, LCS-eligible current smokers were randomized into 3 treatments: quitline (QL), QL plus (QL+), or integrated care (IC). The study was conducted from July 2017 to June 2022 at a hospital-based tobacco treatment clinic in Houston, Texas.

Interventions

The QL intervention group had quitline referral and 12-week nicotine replacement therapy (NRT). The QL+ group had quitline referral plus 12-week NRT or pharmacotherapy prescribed by the LCS clinician. The IC group had 12-week NRT or prescription pharmacotherapy and counseling provided by tobacco treatment specialists within the LCS health care environment. Main Outcomes and Measures The original primary outcome was biochemically verified 7-day point prevalence abstinence at 6 months; however, this was changed to self-reported abstinence during the conduct of the study due to COVID-19 pandemic restrictions.

Results

Of 630 participants, 320 (50.8%) were male, and the median (IQR) age was 59 (55-64) years. Participants smoked a median (IQR) of 20 (15-25) cigarettes per day. Each cohort (QL, QL+, and IC) was composed of 210 participants. The median (IQR) number of counseling sessions was 4 (2-5) sessions for both QL and QL+ and 8 (7-9) sessions for IC. At 3 months, 53 participants (25.2%) in QL, 57 (27.1%) in QL+, and 78 (37.1%) in IC reported abstinence. IC outperformed both QL (odds ratio [OR], 1.75 [95% CI, 1.15-2.66]; P = .01) and QL+ (OR, 1.58 [95% CI, 1.05-2.40]; P = .03). At 6 months, IC maintained the highest rate of abstinence with 68 individuals (32.4%), followed by QL+ at 58 (27.6%) and QL at 43 (20.5%). IC outperformed QL at this time point (OR, 1.86 [95% CI, 1.19-2.89]; P = .01). In the bayesian analysis, IC demonstrated a higher probability of positive absolute risk differences (ARDs) in abstinence at 3 months vs QL (ARD, 0.12) with 99% probability of positive ARD, and QL+ (ARD, 0.10) with 98% probability of positive ARD. This advantage was maintained at 6 months with ARDs of 0.12 for QL (probability of positive ARD, 99%) and 0.05 for QL+ (probability of positive ARD, 86%). Conclusions and Relevance In this randomized clinical trial, IC involving medication and intensive counseling provides the best opportunity for smoking cessation relative to QL counseling, with or without LCS clinician–managed medication. Although IC consistently outperformed QL and QL+, differences with QL+ were reduced at 6 months, suggesting QL+ could be considered in low-resource settings. Trial Registration ClinicalTrials.gov Identifier: NCT03059940

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Detection of CancerLung NeoplasmsSmoking CessationTobacco Use Cessation DevicesAgedFemaleHumansMaleMiddle AgedCounselingTexas

Autor:innen und Institutionen

  • Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.
  • Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston.
  • RVO Health, Fort Mill, South Carolina.
  • Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.
  • School of Medicine and School of Public Health, University of California, Los Angeles.
  • Center for Clinical Research and Evidence-Based Medicine, Department of Pediatrics, The University of Texas at Houston Health Sciences Center, Houston.

Förderung

  • NCI NIH HHS

Zitieren

APA

Cinciripini, P. M., Minnix, J. A., Kypriotakis, G., Erasmus, J., Beneventi, D., Karam-Hage, M., Carpenter, K., Volk, R. J., Carter, B., Godoy, M. C. B., Strange, C., Shih, Y. T., Cui, Y., Green, C. E., & Robinson, J. D. (2025). Smoking Cessation Interventions in the Lung Cancer Screening Setting. JAMA Internal Medicine, 185(3), 284. https://doi.org/10.1001/jamainternmed.2024.7288

Vancouver

Cinciripini PM, Minnix JA, Kypriotakis G, Erasmus J, Beneventi D, Karam-Hage M, et al. Smoking Cessation Interventions in the Lung Cancer Screening Setting. JAMA Internal Medicine. 2025;185(3):284. doi:10.1001/jamainternmed.2024.7288

BibTeX
@article{Cinciripini2025,
  author = {Cinciripini, Paul M and Minnix, Jennifer A and Kypriotakis, George and Erasmus, Jeremy and Beneventi, Diane and Karam-Hage, Maher and Carpenter, Kelly and Volk, Robert J and Carter, Brett and Godoy, Myrna C B and Strange, Chad and Shih, Ya-Chen Tina and Cui, Yong and Green, Charles E and Robinson, Jason D},
  title = {Smoking Cessation Interventions in the Lung Cancer Screening Setting},
  journal = {JAMA Internal Medicine},
  year = {2025},
  volume = {185},
  number = {3},
  pages = {284},
  doi = {10.1001/jamainternmed.2024.7288}
}
Kostenlos starten →